Enhancement of the Antitumor Effect of 1,3-bis(2-Chloroethyl)-1-Nitrosourea (BCNU) by Phenylethylbiguanide (Phenformin)

1 January 1976

journal article
research article
Published by S. Karger AG in Oncology

Vol. 33 (5-6) , 257-259
https://doi.org/10.1159/000225159

Abstract

Phenylethylbiguanide (phenformin), a commonly used antidiabetic medication, enhanced the antitumor effect of BCNU in advanced s.c. implanted mouse L1210 leukemia. Enhancement required 2 doses of phenformin given 12-18 h apart, the treatment starting before or after BCNU administration. With BCNU alone median survival (MS) was 18 days with 5% cures. BCNU plus phenformin, in optimal dose and schedule, gave an MS of 25 days with 29% cures. The mechanism of action of phenformin is unknown but may involve several established metabolic effects of this drug.

Keywords

SEROLOGY

This publication has 2 references indexed in Scilit:

Bronchogenic carcinoma and thromboembolic disease
JAMA, 1967
The Internal Milieu of Tumors
Published by S. Karger AG ,1966